Turn crop yields, farming trends, and resource data into focused market strategies.
Agricultural biologicals are one of the fastest growing segments in the agriculture industry. Biologicals are derived from a combination of naturally occurring microorganisms, insects, extracts, and other such organic substances. Biologicals fit perfectly in the growing trends of organic fertilizer use. Increasing awareness regarding the use of chemical and synthetic fertilizers has encouraged agro-professionals to adopt organic products. Recent advances in biologicals and their nutritional content have led to a wider adoption of the product across the world. Several studies have indicated that the quality of overall crop produce is much better when organic fertilizers are used and have minimum effects on the human health when consumed; contrary to the use of chemicals. Biologicals are becoming a popular product among people across the world. Factors such as clean labelling will also aid the use of biologicals. The reports in this domain are crafted through extensive research analysis methods that are carried out in agricultural activities in several regions across the globe.
The global agricultural microbials market size is projected to grow from $9.53 billion in 2025 to $35.63 billion by 2034, exhibiting a CAGR of 16.11%... Read More
The global bionematicides market size is projected to grow from $819.94 million in 2026 to $1409.88 million by 2034, exhibiting a CAGR of 7.01%... Read More
The global biofertilizers market size is projected to grow from $3.13 billion in 2026 to $8.09 billion by 2034, at a CAGR of 12.60% during the forecast period... Read More
The global biostimulants market size is projected to grow from $5.07 billion in 2026 to $12.86 billion by 2034, at a CAGR of 12.34% during the forecast period... Read More
The global biopesticides market size is projected to grow from $11.48 billion in 2026 to $40.61 billion by 2034, exhibiting a CAGR of 17.11%... Read More
The global agricultural biologicals market size is projected to grow from USD 19.49 billion in 2026 to USD 57.84 billion by 2034, exhibiting a CAGR of 14.57% during...... Read More
The global transplant diagnostics market size is valued at USD 2.82 billion in 2026 and is projected to reach USD 4.45 billion by 2034, exhibiting a CAGR of 5.89% du...... Read More
The global kairomones market size is projected to grow from $1039.4 million in 2026 to $3180.55 million by 2034, exhibiting a CAGR of 14.99%.... Read More
The global agricultural pheromones market size is expected to grow from $6.67 billion in 2026 to $24.86 billion by 2034, exhibiting a CAGR of 17.87%... Read More
The global semiochemicals market is projected to grow from $7.24 billion in 2026 to $23.68 billion by 2034, at a CAGR of 15.97% over the forecast period... Read More
The Romania biostimulants market size was valued at $50.25 million in 2024 & is projected to grow from $53.70 million in 2025 to $87.18 million by 2032... Read More
The Canada biofertilizers market size is projected to grow at a CAGR of 10.58% during the forecast period.... Read More
The U.S. biofertilizers market size was $523.46 million in 2024 & is projected to grow from $584.41 million in 2025 to $1,288.30 million by 2032... Read More
The Brazil biofertilizers market size is estimated to grow at a CAGR of 13.87% during the forecast period.... Read More
The China biofertilizers market size is projected to grow at a CAGR of 13.07% during the forecast period.... Read More
The India biostimulants market size is projected to grow from $410.78 million in 2025 to $1,135.96 million by 2032, exhibiting a CAGR of 15.64%.... Read More
The India agricultural biologicals market size is projected to grow from $652.50 million in 2025 to $1,646.03 million by 2032, exhibiting a CAGR of 14.13%.... Read More
The U.S. and Europe biostimulants market size is projected to grow from $2,171.87 million in 2024 to $4,905.66 million by 2032 exhibiting at a CAGR of 10.72%... Read More
The India agricultural pheromones market is projected to grow from $4.05 million in 2022 to $11.03 million by 2029, at a CAGR of 15.40% in forecast period... Read More
The India biofertilizers market is expected to grow from $110.07 million in 2022 to $243.61 million by 2029, exhibiting a CAGR of 12.02% in forecast period... Read More
The primary objective of these reports is to provide data-driven insights about the healthcare burden, healthcare resources, healthcare infrastructure, healthcare services and installed base of key medical equipment. These reports can play a crucial role in the assessment of market potential based on healthcare needs and penetration of medical devices and drive the strategies to increase the demand for healthcare products.
Global healthcare spending reached USD 11.1 trillion in 2024 due to the evolving healthcare needs driven by the aging population and growth in burden of chronic diseases.
In 2024, healthcare expenditure accounted for roughly 10.0% of the global GDP. Although the per capita healthcare spending was around USD 1,354 globally, there is a huge disparity among developed and developing nations.
| Per Capita Healthcare Spending | |
|---|---|
| U.S. | USD 12,740 |
| Japan | USD 3,890 |
| China | USD 675 |
| Indonesia | USD 395 |
| India | USD 102 |
| Number of doctors per 1,000 people | |
|---|---|
| High-income countries | 3.7 |
| Middle-income countries | 2.3 |
| Low-income countries | 0.4 |
In terms of the healthcare infrastructure such as hospitals and hospitals beds, the disparity between developed, developing and under-developed countries is significant, similar to the data on healthcare spending and healthcare resources.
| Number of ICU beds per 100,000 people | |
|---|---|
| High-income countries | 12.8 |
| Middle-income countries | 5.6 |
| Low-income countries | Less than 2.5 |
This scope can be covered for the following set of countries:
The primary objective of epidemiology reports is to provide data-driven insights into the incidence, prevalence, and distribution of diseases across different populations, geographies and time periods. These reports can play a crucial role in the assessment of market potential based on patient populations and drive the strategies for the development for healthcare products such as pharmaceuticals, medical devices, or diagnostics. Epidemiology reports include segmentation by age, gender, region, and disease stage, enabling companies to make informed decisions about market entry, product positioning, and clinical trial planning.
Assist in the estimation of the potential/addressable market based on patient population
Provide an understanding of the trend in patient population
Provide an overview of the cost of care & therapeutics market
Provide an understanding of the disease landscape
Provide an understanding of the treated patient population
We can check the feasibility of adding specific countries to the geographic scope based on your requirements.
USA
UK
Germany
France
Italy
Spain
Japan
China
India
AustraliaGlobally, chronic diseases account for almost three-quarters of all deaths. At present, more than one in three adults have at least one chronic condition. Unhealthy lifestyle and ageing population are some of the main factors contributing to the growing burden of non-communicable diseases such as diabetes and cardiovascular conditions.
Management of chronic diseases and treatment of conditions due to these chronic diseases accounts for a significantly large proportion of the total healthcare spending of all countries, developed as well as
In the U.S., around 90% of the annual healthcare spending is on people suffering from chronic and mental conditions.
The World Economic Forum estimates that the global cost of treating chronic diseases will be around USD 30 trillion by 2030.
| DISEASE INDICATION |
U.S | U.K | Germany | France | Italy | Spain | Saudi Arabia | United Arab Emirates |
|---|---|---|---|---|---|---|---|---|
| Diabetes | 32.5 | 4.0 | 6.2 | 4.0 | 4.5 | 5.2 | 4.4 | 1.0 |
| Hypertension | 148.2 | 23.2 | 30.7 | 22.2 | 25.3 | 15.7 | 15.2 | 5.3 |
| Kidney Stone | 0.67 | 0.30 | 0.38 | 0.29 | 0.26 | 0.27 | 0.13 | 0.03 |
| Obesity | 109.3 | 23.6 | 21.3 | 13.6 | 10.4 | 10.3 | 10.1 | 3.9 |
Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. If it is not treated, cancer can invade surrounding tissues and spread to other parts of the body.
Around 20 million new cancer cases are diagnosed every year with men accounting for roughly 51% of them. China, India, USA and Japan account for around 4% of new cancer cases globally.
| Type | Cancer Incidence |
|---|---|
| Trachea, Bronchus & Lung | 2.5 |
| Breast | 2.3 |
| Colorectum | 1.9 |
| Prostate | 1.5 |
| Stomach | 0.97 |
| Liver | 0.87 |
| Thyroid | 0.82 |
| Cervix Uteri | 0.66 |
| Bladder | 0.61 |
| Non-Hodgkin Lymphoma | 0.55 |
Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer account for around 44% of the new cancer cases (excluding non-melanoma skin cancer).
Diabetes is a chronic medical condition in which the body either doesn't produce enough insulin or can't effectively use the insulin it produces, leading to elevated levels of glucose in the blood. Over time, high blood sugar can cause serious damage to the heart, kidneys, eyes, and nerves.
Around 540 million people suffer from diabetes globally with more than 40% of the cases undiagnosed.
The two main types of diabetes are Type 1 and Type2. Type 1 is an autoimmune condition where the body destroys insulin-producing cells, requiring lifelong insulin therapy whereas Type 2 is a metabolic disorder where the body either doesn't produce enough insulin or cells become resistant to its effects. Type 2 accounts for around 96% of the prevalent diabetes cases.
Type 1
12,504,087 (4.4%)Type 2
269,376,970 (95.6%)0–19 yrs
579,27620–44 yrs
46,553,35345–64 yrs
91,116,784>64 yrs
143,631,644Men
146,030,908 (51.8%)Women
135,850,149 (48.2%)Conditions that impair the function of the kidneys, which are responsible for filtering waste and excess fluids from the blood, are known as kidney diseases. These diseases can range from acute kidney injury to chronic kidney disease (CKD), which may progress to kidney failure if not managed properly. Common causes include diabetes, high blood pressure, infections, and genetic disorders.
Globally, around 700 million people are estimated to be suffering from chronic kidney disease (CKD). Around 14% of adults in the U.S. are estimated to have CKD. Kidney diseases account for almost 2-4% of the total healthcare budgets in many developed nations. In the U.S., the annual cost of kidney diseases is estimated to be more than USD 85 billion.
Around 2 million people worldwide suffer from end-stage renal disease (ESRD), for which they receive dialysis or kidney transplants.
|
USA
|
750,000 |
|
Japan
|
350,000 |
|
Brazil
|
200,000 |
|
Germany
|
80,000 |
|
UK
|
70,000 |
A condition affecting less than 65 per 100,000 people is defined as a rare disease by the WHO. The global prevalence of more than 7,000 rare diseases together is around 300 million. More than 65% of the patients suffering from rare diseases are children and majority of these diseases do not have any treatment.
| Cystic Fibrosis | Lou Gehrig's Disease (ALS) | Huntington's Disease | Duchenne Muscular Dystrophy (DMD) |
|---|---|---|---|
| 40,000 | 18,000 | 30,000 | 15,000 |
Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions like coronary artery disease, heart failure, stroke, and hypertension. They are the leading cause of death globally, often resulting from a combination of lifestyle factors and underlying health conditions.
It is estimated that around 60% of the U.S. adults will have some form of cardiovascular disease (CVD) in the next 30 years and the cost (direct and indirect) of CVD will be around USD 1.8 trillion. Globally, around 700 million people are living with CVDs and CVDs account for around one in three deaths every year.
Download Sample